Title: Investigation of RRM2 as a potential therapeutic target against glioblastoma Supervisors: Dr. Sven Nelander and Mr. Sathishkumar Baskaran. Department: Department of Immunology, genetics and pathology (IGP), Uppsala University Glioblastoma (GBM) is the most malignant form of glioma and associated with high proliferation rate, necrosis and highly invasive nature. Current treatment includes tumor resection followed by combination of radiotherapy and chemotherapy with temozolomide (TMZ). Despite of combination therapy, GBM exhibits dismal prognosis and mean survival rate of patients is only 3.3 % at 2 years and 1.2 % at 3 years. Therefore, there is an increasing demand of identifying new therapeutic targets against GBM. In this project, we studied the function of RRM2 gene as a potential therapeutic target in two patients derived GBM cell lines (GC). By knocking down RRM2 using short interfering RNAs, the viability of cells and proliferation was significantly reduced in both the GC. The cause of cell death was due to induction of apoptosis by the treatment in GC. Treatment of COH29, an inhibitor of RNR, induced cell death at therapeutically relevant dose in GC. Our results indicate that RRM2 has a significant role in GBM cell growth/proliferation. More evaluation must be performed in both in-vitro and in-vivo to pursue RRM2 as a molecular therapeutic target against GBM.
| Identifer | oai:union.ndltd.org:UPSALLA1/oai:DiVA.org:uu-337136 |
| Date | January 2017 |
| Creators | Hekmati, Neda |
| Publisher | Uppsala universitet, Institutionen för biologisk grundutbildning |
| Source Sets | DiVA Archive at Upsalla University |
| Language | English |
| Detected Language | English |
| Type | Student thesis, info:eu-repo/semantics/bachelorThesis, text |
| Format | application/pdf |
| Rights | info:eu-repo/semantics/openAccess |
Page generated in 0.0129 seconds